Document Detail


Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator.
MedLine Citation:
PMID:  11692295     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Treatment failures for leishmaniasis with pentavalent antimonials, including meglumine antimonate, are increasingly common in many endemic areas. Imiquimod (Aldara; 3M Pharmaceuticals) is a novel immune response-activating compound, approved by the United States Food and Drug Administration, that is currently used to treat cervical warts and has been shown to activate macrophage killing of Leishmania species. Therefore, an open-label, prospective study was conducted of combined imiquimod plus meglumine antimonate therapy in 12 patients with cutaneous leishmaniasis who had previously not responded to meglumine antimonate therapy. All of the patients responded well to this combination therapy, and 90% were found to be cured at the 6-month follow-up period.
Authors:
I Arevalo; B Ward; R Miller; T C Meng; E Najar; E Alvarez; G Matlashewski; A Llanos-Cuentas
Related Documents :
18525285 - Factors affecting usage patterns of memantine in alzheimer disease.
12943655 - Sulfonation of environmental estrogens by zebrafish cytosolic sulfotransferases.
18184165 - Hyponatremia as a complication of selective serotonin reuptake inhibitors.
18640705 - Occurrence of diclofenac and selected metabolites in sewage effluents.
3997485 - Nutritional status of the institutionalized elderly.
22260845 - Physical and chemical control of the phytoplankton of ahe lagoon, french polynesia.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2001-10-23
Journal Detail:
Title:  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America     Volume:  33     ISSN:  1537-6591     ISO Abbreviation:  Clin. Infect. Dis.     Publication Date:  2001 Dec 
Date Detail:
Created Date:  2001-11-05     Completed Date:  2001-12-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9203213     Medline TA:  Clin Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1847-51     Citation Subset:  IM    
Affiliation:
Department of Microbiology and Immunology, McGill University, and Department of Tropical Medicine, McGill University Hospital Complex, Montreal, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / therapeutic use*
Adolescent
Adult
Aminoquinolines / therapeutic use*
Antiprotozoal Agents / therapeutic use*
Child
Child, Preschool
Drug Resistance*
Drug Therapy, Combination
Female
Humans
Infant
Leishmaniasis, Cutaneous / drug therapy*,  pathology
Male
Meglumine / therapeutic use*
Middle Aged
Organometallic Compounds / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Aminoquinolines; 0/Antiprotozoal Agents; 0/Organometallic Compounds; 133-51-7/meglumine antimoniate; 6284-40-8/Meglumine; 99011-02-6/imiquimod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment of the clinical presentation and treatment of 353 cases of laboratory-confirmed leptospir...
Next Document:  Enzyme immunoassay for the diagnosis of cat-scratch disease defined by polymerase chain reaction.